Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: UMLS:C0022104 (irritable bowel syndrome)
8,033 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We have recently demonstrated that N(6)-cyclopentyladenosine (CPA), an adenosine A1 receptor agonist, acts centrally to induce a visceral antinociception. Since serotonin (5-HT), cannabinoid (CB), dopamine or opioid signaling in the central nervous system is involved in the regulation of visceral sensation, we made a hypothesis that the signaling may play a role in the CPA-induced visceral antinociception. Visceral sensation was evaluated by colonic distension-induced abdominal withdrawal reflex (AWR) in conscious rats. Subcutaneously administered CPA significantly increased the threshold of colonic distension-induced AWR. Intracisternal injection of either 5-HT_1A or 5-HT_2A receptor antagonist blocked the CPA-induced visceral antinociception while 5-HT_1B antagonist did not block the CPA-induced visceral antinociception. Subcutaneous injection of dopamine D₁ receptor antagonist, CB₁ receptor antagonist or naloxone significantly blocked the CPA-induced visceral antinociception while neither subcutaneous injection of dopamine D₂ receptor antagonist nor CB₂ receptor antagonist blocked the CPA-induced anti-pain action. These results suggest that 5-HT_1A, 5-HT_2A, dopamine D₁, CB₁ receptors and the opioid system in the CNS may specifically mediate the CPA-induced visceral antinociception. These findings may help in understanding the physiological relevance of central adenosine with special reference to the pathophysiology of altered visceral sensation especially in irritable bowel syndrome.
...
PMID:Adenosine A₁ receptor agonist induces visceral antinociception via 5-HT_1A, 5-HT_2A, dopamine D₁ or cannabinoid CB₁ receptors, and the opioid system in the central nervous system. 3219 97

---